1. Home
  2. CERO vs MBIO Comparison

CERO vs MBIO Comparison

Compare CERO & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • MBIO
  • Stock Information
  • Founded
  • CERO 2017
  • MBIO 2015
  • Country
  • CERO United States
  • MBIO United States
  • Employees
  • CERO N/A
  • MBIO N/A
  • Industry
  • CERO
  • MBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CERO
  • MBIO Health Care
  • Exchange
  • CERO Nasdaq
  • MBIO Nasdaq
  • Market Cap
  • CERO 8.4M
  • MBIO 7.3M
  • IPO Year
  • CERO N/A
  • MBIO N/A
  • Fundamental
  • Price
  • CERO $1.92
  • MBIO $2.93
  • Analyst Decision
  • CERO
  • MBIO Strong Buy
  • Analyst Count
  • CERO 0
  • MBIO 1
  • Target Price
  • CERO N/A
  • MBIO $100.00
  • AVG Volume (30 Days)
  • CERO 787.1K
  • MBIO 411.9K
  • Earning Date
  • CERO 02-20-2025
  • MBIO 03-10-2025
  • Dividend Yield
  • CERO N/A
  • MBIO N/A
  • EPS Growth
  • CERO N/A
  • MBIO N/A
  • EPS
  • CERO N/A
  • MBIO N/A
  • Revenue
  • CERO N/A
  • MBIO N/A
  • Revenue This Year
  • CERO N/A
  • MBIO N/A
  • Revenue Next Year
  • CERO N/A
  • MBIO N/A
  • P/E Ratio
  • CERO N/A
  • MBIO N/A
  • Revenue Growth
  • CERO N/A
  • MBIO N/A
  • 52 Week Low
  • CERO $1.76
  • MBIO $2.61
  • 52 Week High
  • CERO $1,238.00
  • MBIO $74.50
  • Technical
  • Relative Strength Index (RSI)
  • CERO 33.62
  • MBIO 29.06
  • Support Level
  • CERO $1.77
  • MBIO $3.96
  • Resistance Level
  • CERO $2.22
  • MBIO $6.70
  • Average True Range (ATR)
  • CERO 0.36
  • MBIO 0.87
  • MACD
  • CERO 0.29
  • MBIO -0.07
  • Stochastic Oscillator
  • CERO 11.27
  • MBIO 7.94

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: